This suite of available technologies addresses topical administration of pain-relieving drugs to the peripheral tissues and offers important advantages over systemic administration. Compositions are provided for combinatorial topical applications to treat mucus membrane cavity pain (i.e. mucositis) as well as topical pain syndromes involving the skin (i.e. peripheral neuropathies, burns, trauma, etc.). Additionally, other compositions are provided which yield previously unknown synergistic effects of topically applied opioids, anesthetics or NMDA receptor antagonists that can provide even more analgesic activity. The topical administration described in these technologies circumvents difficulties associated with the severity of the side effects associated with opiates administered by other means.
- No demonstrated systemic physical dependence following repeated use
- No sedation or respiratory depression
- No hormonal effects
- No effects exerted on gastrointestinal function
- Oral mucositis associated with cancer or dental pain associated with surgery
- Analgesic for topical use on the skin
Demonstration of effective pain relief in mouse models of pain. Lead inventor is eager to bring products covered by the claims of the patents to the clinic.
Gavril Pasternak, MD, PhD, Laboratory Head, Molecular Pharmacology & Chemistry Program, Sloan Kettering Institute, Memorial Sloan Kettering
U.S. patents issued: